Sort   by:  
 Page size 
UnknownA prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
Not available
S-EPMC5780540 | biostudies-literature
UnknownPatient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Not available
S-EPMC5909214 | biostudies-literature
UnknownGlobal status quo and trends of research on urinary incontinence: a bibliometric and visualized study.
Not available
S-EPMC10754693 | biostudies-literature
UnknownCost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.
Not available
S-EPMC5434500 | biostudies-literature
UnknownEfficacy and Safety of Mirabegron in Males with Overactive Bladder and Lower Urinary Tract Symptoms: Analysis from an Integrated Database.
Not available
S-EPMC12617816 | biostudies-literature
UnknownPooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database.
Not available
S-EPMC5935888 | biostudies-literature
UnknownWhat are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine.
Not available
S-EPMC8362045 | biostudies-literature
UnknownSafety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.
Not available
S-EPMC7473960 | biostudies-literature
UnknownPatients' perspective of telephone visits during the COVID-19 pandemic.
Not available
S-EPMC7492037 | biostudies-literature
UnknownOnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.
Not available
S-EPMC4282287 | biostudies-literature
Sort   by:  
 Page size